Reply to the letter from Drs Matutes and Catovsky Leukemia (2003) 17, 1683. doi:10.1038/sj.leu.2403002
TO THE EDITOR
The point of our letter in the December 2002 issue of Leukemia 1 was simply to suggest that there are likely to be mature T-cell leukemias which do not represent one of the entities recognized by the recent WHO classification of lymphoid neoplasms. 2 These entities include T-cell prolymphocytic leukemia (T-PLL), adult T-cell leukemia/ lymphoma, mycosis fungoides/Sezary syndrome, T-cell large granular lymphocytic leukemia, and, potentially, peripheral T-cell lymphoma with a leukemic component. The existence of such problematic cases is suggested by a recent case report which contained both karyotypic information and follow-up data. 3 In that report, Soma and co-workers describe a 73-year-old male with a chronic mild lymphocytosis which would be best classified as T-PLL under the WHO classification, yet which demonstrated multiple cytogenetic abnormalities without the characteristic inv(14) (q11q32) or t(14;14)(q11;q32) of T-PLL, and which showed remarkably indolent clinical behavior compared to T-PLL. While the median survival in T-PLL is less than 1 year, 2 this patient was reportedly asymptomatic without therapy for over 7 years, leading the authors to speculate whether this case represented a T-CLL-like entity. Follow-up of this patient will be very useful to determine whether the acquisition of trisomy 8 in the most recent cytogenetic evaluation of this leukemia portends a more aggressive clinical behavior, as chromosome 8 abnormalities are common in T-PLL. 2 By suggesting that an additional entity in the WHO classification may be useful for mature T-cell leukemias without the characteristic morphology and genetic lesions of T-PLL, we are not proposing to move the field back to the T-CLL/T-PLL category of the REAL classification. Rather, we would hope that such an admittedly illdefined new entity would only represent an interim category, and would provide the basis for additional research in the field aimed at defining the range of mature T-cell leukemias at the molecular level.
To emphasize that such a disease category reflects uncertainty as to the biology of the cases grouped within it, and to emphasize that this category should not be viewed as a resurrection of T-CLL, we believe that the designation 'mature T-cell leukemia, not otherwise specified' might represent an adequate way to describe such neoplasms for the time being. Identification of CD14 as a predictor for leukemic dendritic cell differentiation in acute myeloid leukemia + cells of acute myeloid leukemia (AML) patients represent the leukemic compartments that can be induced in vitro to acquire the mature dendritic cell (DC) phenotype in the presence of GM-CSF, IL-4 and CD40L. In contrast, culture of the CD14
À subpopulations did not result in the generation of leukemic DC. In our laboratory, we generate leukemic DC from AML blasts by the use of a cytokine cocktail. 2 We also observed a correlation between the percentage of CD14 expression on AML blasts and AML-DC culture outcome, as defined by the percentage of CD40 + /CD86 + cells at the end of culture (n ¼ 33, Spearman's r : 0.51, P ¼ 0.002). In contrast to Mohty et al, we were able to culture leukemic DC in 5/19 (26%) of the CD14 À AML patients. The discrepancy between these observations could be related to several aspects. Firstly, in our immunophenotypic analysis we gated specifically on the CD45 dim blast population, resulting in a welldefined leukemic blast population. Secondly, the culture method used by Mohty et al, is typically used to culture monocyte-derived DC. 3, 4 We observed that it is more effective to use an alternative culture method for the induction of DC differentiation in AML samples. We use a combination of various cytokines, namely, GM-CSF, TNF-a, SCF, Flt3-L, IL-3 and IL-4 resulting in functionally active (as measured by mixed lymphocyte reaction) leukemic DCs in 14 days. Additionally, a culture method based on the use of calcium ionophores (CI), thereby bypassing receptor-mediated signaling, is able to further increase the percentage of successful AML-DC cultures, even in CD14 À AML samples. 2 In a population of 33 AML patients, blasts of 19 (58%) patients showed less than 15% CD14 expression. In five (26%) AML samples, we were able to generate leukemic DC by the use of the described cytokine cocktail. More importantly, by culturing AML blasts with the CI A23187 and IL-4 for only 2 days, we generated mature functionally active leukemic DC in 10 out of 15 CD14
À AML samples tested (Table 1) . Recently, we have shown that serum-free culture of AML-DC is feasible and that these DC are comparable to serum-enriched cultured AML-DC with regard to morphological, immunophenotypical and functional characteristics. 5 Overall, these results indicate that the serum-free culture of AML-DC derived from CD14 À AML blasts, by the use of CI, is feasible in 71% of the AML patients. The use of CI provides an excellent alternative method for the induction of DC differentiation in CD14
À AML samples, thus enabling the development of vaccination programs for this subgroup of AML patients. 
In a recent issue of Leukemia, 1,2 we have reported that dendritic cells (DC) generated from acute myeloid leukemia (AML) patients in the presence of GM-CSF, IL-4 and matured with CD40L can be obtained from two major precursors: DC derived from CD14+ leukemic cells and/or leukemic DC derived from the previously described in vivo expanded circulating blood myeloid DC (MDC). 3 Leukemic DC of both subsets exhibited DC morphology, had a phenotype of mature DC (CD83+), and could induce a potent proliferative response of naive CD4+ T cells. Moreover, both subsets produced large amounts of bioactive IL-12p70. 1 Interestingly, in accordance with our findings, van de Loosdrecht et al 4 also observed a correlation between the percentage of CD14 expression on AML blasts and leukemic DC yield (although defined by the expression of nonspecific DC markers such as CD40 and CD86). 4 Moreover, these authors were able to obtain leukemic DCs in five cases of CD14À AML patients. Again, the latter can be in line with our previous studies, showing that expanded circulating blood MDCs in AML patients are another precursor of leukemic DCs. Indeed, expanded leukemic MDCs that represent the leukemic counterpart of the normal circulating MDC subset, do not express CD14 or any other lineage marker. Thus, it is likely that in the five cases described by van de Loosdrecht et al, leukemic DCs could have been generated from an expanded peripheral blood MDC compartment, which lacks CD14 expression. As suggested by van de Loosdrecht et al, the use of calcium ionophores (CI) might represent an attractive modality for leukemic DC generation. However, at present, the exact impact of CI on DC development, differentiation and functions, is still unknown. Therefore, a detailed functional characterization of leukemic CI-derived DCs as for phenotype, cytokine secretion profile, type of T-helper responses, induction of specific cytotoxic T-lymphocytes and chemokine receptors expression, is mandatory before any therapeutic application. 
